AKT1 and cancer: A potential mechanism hindering rapamycin cancer treatment could be the loss of the negative feedback circuit from PI3K/AKT/mTORC1 signaling to the PI3K/AKT/mTORC2 signaling axis, which is mediated via ribosomal protein S6K [130] (Figure 2).